In Brief
Refine Search
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Biotechnology
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Biosimilars
Gedeon Richter today announced that the European Medicines Agency (EMA) has accepted the company’s two marketing authorization applications (MAAs) for its proposed biosimilar to denosumab. 19 July 2024
Biotechnology
Israel’s Teva Pharmaceutical Industries has presented positive topline results from its Phase III SPACE study of Ajovy (fremanezumab) for the prevention of episodic migraine in children and adolescent patients aged six to 17 years. 19 July 2024
Pharmaceutical
The National Institute for Health and Care Excellence’s (NICE), the cost-effectiveness watchdog for England and Wales, has published a Final Appraisal Document recommending the reimbursement of Orgovyx (relugolix) in prostate cancer. 19 July 2024
Pharmaceutical
French drugmaker Sanofi (Euronext: SAN) is reportedly planning a significant investment of over $400 million in its “global capacity center,” in Hyderabad, India. 19 July 2024
Pharmaceutical
Ardelyx has filed a lawsuit against the US Department of Health and Human Services DHSS) and the Centers for Medicare and Medicaid Services (CMS), regarding its Xpohzah. 19 July 2024
Biotechnology
Californian start-up Caribou Biosciences (Nasdaq: CRBU) has announced significant workforce reductions, cutting approximately 12% of its staff. 19 July 2024
Pharmaceutical
In New York, biotech firm Synaptogenix (Nasdaq: SNPX) has announced a new collaboration with LSU Health New Orleans. 19 July 2024
Pharmaceutical
Ono Pharmaceuticalannounced that the European Medicines Agency (EMA) has accepted the marketing authorization application (MAA) for vimseltinib. 19 July 2024
Biotechnology
Roche has announced two-year data from the Phase III Pagoda and Pavilion studies evaluating Susvimo 19 July 2024
Pharmaceutical
Boston, USA-based AVEO Oncology, a subsidiary of LG Chem (KRX: 051910), has announced that the TiNivo-2 Phase III trial did not meet its primary efficacy endpoint. 19 July 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has approved Voquezna (vonoprazan) 10 mg tablets for the relief of heartburn associated with non-erosive gastroesophageal reflux disease (non-erosive GERD). 18 July 2024
Pharmaceutical
German family-owned pharma major Boehringer Ingelheim today reported significant progress in its pipeline across key therapeutic areas as it reached major milestones in the first half of the year. 18 July 2024
Pharmaceutical
An Expert View from William Hind of Alpharmaxim and Lisa Campbell of SSI Strategy. 18 July 2024
Biotechnology
Swedish firm Enzymatica (STO: ENZY) will conduct a rights issue to raise approximately $12 million, with existing shareholders being given preferential rights. 18 July 2024
Biosimilars
Privately-held German drugmaker Boehringer Ingelheim has inked a deal with GoodRx (Nasdaq: GDRX), in a bid to boost US penetration of its biosimilar to Humira (adalimumab). 18 July 2024
Pharmaceutical
60% of listed Indian pharmaceutical companies have experienced an uptick in new business inquiries from US pharma companies due to the discussions around the US Biosecure Act. 18 July 2024
Pharmaceutical
A new research paper concluding that the use of Inpefa (sotagliflozin) for the treatment of patients hospitalized for heart failure (HF) and suffering from co- morbid diabetes leads to significant positive impact on provider health system financial outcomes. 18 July 2024
Pharmaceutical
Boehringer Ingelheim has entered partnership with AI company Brainomix for a collaborative program of activity to improve the care of patients with fibrosing lung disease in the USA. 18 July 2024
Biotechnology
The show is over for Aslan Pharmaceuticals, the immunology-focused biopharmaceutical company, as its financial troubles have led it to file for voluntary liquidation. 18 July 2024
Biotechnology
French pharma major Sanofi announced that full results from the XTEND-Kids Phase III study have been published in The New England Journal of Medicine (NEJM). 18 July 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze